Cargando…

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children

We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Biggelaar, Anita H. J., Pomat, William S., Masiria, Geraldine, Wana, Sandra, Nivio, Birunu, Francis, Jacinta, Ford, Rebecca, Passey, Megan, Kirkham, Lea-Ann, Jacoby, Peter, Lehmann, Deborah, Richmond, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466212/
https://www.ncbi.nlm.nih.gov/pubmed/30720721
http://dx.doi.org/10.3390/vaccines7010017
_version_ 1783411056558735360
author van den Biggelaar, Anita H. J.
Pomat, William S.
Masiria, Geraldine
Wana, Sandra
Nivio, Birunu
Francis, Jacinta
Ford, Rebecca
Passey, Megan
Kirkham, Lea-Ann
Jacoby, Peter
Lehmann, Deborah
Richmond, Peter
author_facet van den Biggelaar, Anita H. J.
Pomat, William S.
Masiria, Geraldine
Wana, Sandra
Nivio, Birunu
Francis, Jacinta
Ford, Rebecca
Passey, Megan
Kirkham, Lea-Ann
Jacoby, Peter
Lehmann, Deborah
Richmond, Peter
author_sort van den Biggelaar, Anita H. J.
collection PubMed
description We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 μg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes.
format Online
Article
Text
id pubmed-6466212
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64662122019-04-18 Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children van den Biggelaar, Anita H. J. Pomat, William S. Masiria, Geraldine Wana, Sandra Nivio, Birunu Francis, Jacinta Ford, Rebecca Passey, Megan Kirkham, Lea-Ann Jacoby, Peter Lehmann, Deborah Richmond, Peter Vaccines (Basel) Article We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 μg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes. MDPI 2019-02-04 /pmc/articles/PMC6466212/ /pubmed/30720721 http://dx.doi.org/10.3390/vaccines7010017 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van den Biggelaar, Anita H. J.
Pomat, William S.
Masiria, Geraldine
Wana, Sandra
Nivio, Birunu
Francis, Jacinta
Ford, Rebecca
Passey, Megan
Kirkham, Lea-Ann
Jacoby, Peter
Lehmann, Deborah
Richmond, Peter
Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
title Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
title_full Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
title_fullStr Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
title_full_unstemmed Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
title_short Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
title_sort immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine: a randomized controlled trial in papua new guinean children
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466212/
https://www.ncbi.nlm.nih.gov/pubmed/30720721
http://dx.doi.org/10.3390/vaccines7010017
work_keys_str_mv AT vandenbiggelaaranitahj immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT pomatwilliams immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT masiriageraldine immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT wanasandra immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT niviobirunu immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT francisjacinta immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT fordrebecca immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT passeymegan immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT kirkhamleaann immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT jacobypeter immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT lehmanndeborah immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT richmondpeter immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren
AT immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren